| Noble et al. [11] | FVC | ||||||
| Taniguchi et al. [12] | VC | ||||||
| Daniels et al. [13] | PFS# | ||||||
| King et al. [14] | Survival | ||||||
| Raghu et al. [15] | FVC | DL,CO | Pa,O2 | ||||
| King et al. [16] | 6MWT | ||||||
| Kubo et al. [17] | Survival | ||||||
| Demedts et al. [18] | VC | DL,CO | |||||
| Azuma et al. [8] | Pa,O2¶ | 6MWT¶ | |||||
| Raghu et al. [9] | PFS+ |
FVC: forced vital capacity; VC: vital capacity; DL,CO: diffusing capacity of the lung for carbon monoxide; Pa,O2: arterial oxygen tension; 6MWT: 6-min walk test; PFS: progression-free survival. #: time to disease progression defined as decline in FVC (%) from baseline predicted FVC or death; ¶: lowest arterial oxygen saturation measured by pulse oximetry during 6MWT; +: defined as ≥10% decline from baseline of predicted VC or an increase ≥5 mmHg in the alveolar–arterial oxygen tension difference at rest.